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52Polymer-Free Biolimus A9-Coated Stents in the
Treatment of De Novo Coronary Lesions
4- and 12-Month Angiographic Follow-Up and Final 5-Year
Clinical Outcomes of the Prospective, Multicenter BioFreedom
FIM Clinical TrialABSTRACTOBJECTIVES The purpose of this study was to evaluate the efﬁcacy and long-term outcomes of a novel
polymer/carrier-free drug-coated stent (DCS) in patients with de novo coronary lesions.
BACKGROUND The BioFreedom (BFD) DCS incorporates a low-proﬁle, stainless-steel platform, with a surface that has
been modiﬁed to create a selectively microstructured abluminal surface that allows adhesion and further release of
Biolimus A9 (Biosensors Europe SA, Morges, Switzerland).
METHODS A total of 182 patients (183 lesions) were randomized into a 1:1:1 ratio for treatment with BFD “standard
dose” (BFD) or BFD “low dose” (BFD-LD) versus ﬁrst-generation paclitaxel-eluting stents (PES) at 4 sites in Germany.
RESULTS Baseline and procedural characteristics were well matched. At 4-month angiographic follow-up (Cohort 1,
n ¼ 75), in-stent late lumen loss (LLL) was signiﬁcantly lower with BFD and BFD-LD versus PES (0.08 and 0.12 mm vs.
0.37 mm, respectively; p < 0.0001 for BFD vs. PES, and p ¼ 0.002 for BFD-LD vs. PES). At 12 months (Cohort 2,
n ¼ 107), in-stent LLL (primary endpoint) was 0.17 mm in BFD versus 0.35 mm in PES (p ¼ 0.001 for noninferiority;
p ¼ 0.11 for superiority); however, the BFD-LD (0.22 mm) did not reach noninferiority (p ¼ 0.21). At 5 years (175 of 182),
there were no signiﬁcant differences in major adverse cardiac events (23.8%, 26.4%, and 20.3%) and clinically indicated
target lesion revascularization (10.8%, 13.4%, and 10.2%) for BFD, BFD-LD, and PES, respectively; also, there was no
deﬁnite/probable stent thrombosis reported.
CONCLUSIONS The BFD, but not the BFD-LD, demonstrated noninferiority versus PES in terms of in-stent LLL,
a surrogate of neointimal hyperplasia, at 12-month follow-up. At 5 years, clinical event rates were similar, without
occurrence of stent thrombosis in all groups. (BioFreedom FIM Clinical Trial; NCT01172119) (J Am Coll Cardiol Intv
2016;9:51–64) © 2016 by the American College of Cardiology Foundation.SEE PAGE 65N onpolymeric drug-coated stents (DCS) havebeen introduced as an alternative to poly-meric drug-eluting stents (DES), as previ-
ous studies investigating the biocompatibility of
drug carriers—particularly durable polymers used in
ﬁrst-generation DES—had demonstrated negative ef-
fects of these components on vessel healing due to
chronic inﬂammation and local toxicity, which could
lead to proliferative and thrombogenic responses
over time (1–6). In addition, the safety of current
DES systems appears to be dependent on relatively
long ($6 months) dual antiplatelet therapy (DAPT)
(7,8), a fact that may limit their use on a signiﬁcant
proportion of patients with adherence restraints,
such as those at high risk for bleeding (9). However,
the absence of a drug carrier has also been associated
with lesser efﬁcacy at inhibiting neointimalhyperplasia (NIH), most probably due to insufﬁcient
and/or uncontrolled drug delivery at the target coro-
nary site (10–13).BA9 (biolimus), a 31-membered triene macrolide
lactone derivative of sirolimus, is a potent anti-
proliferative agent that has been developed for
vascular applications, speciﬁcally for DES (14). Over-
all, biolimus has consistently demonstrated high ef-
ﬁcacy at inhibiting NIH, as well as sustained safety
when delivered via a biodegradable polymer DES in
multiple clinical scenarios (15–17). Still, the effect of
biolimus released from a polymer/carrier-free DCS
system in human coronary arteries is yet to be
determined. Hence, the purpose of this analysis was
to report the ﬁrst-in-man (FIM) evaluation of a new
AB BR E V I A T I O N S
AND ACRONYM S
BFD = BioFreedom
DCS = drug-coated stent(s)
DES = drug-eluting stent(s)
FU = follow-up
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53polymer-free biolimus-coated stent in the treatment
of de novo coronary lesions. The study hypothesis
was that a polymer-free biolimus release via a
microstructured stent surface (18) could be as effec-
tive in reducing NIH as compared with a ﬁrst-
generation paclitaxel-eluting stent (PES) in diseased
coronary vessels.LD = “low dose”
LLL = late lumen loss
NIH = neointimal hyperplasia
PES = paclitaxel-eluting
stent(s)
TLR = target lesion
revascularizationMETHODS
STUDY DESIGN AND PATIENT POPULATION. The
BioFreedom FIM clinical trial was a prospective,
randomized, single-blinded, multicenter feasibility
study designed to investigate the performance,
safety, and efﬁcacy of the novel polymer-free Bio-
Freedom biolimus-coated stents (Biosensors Europe
SA, Morges, Switzerland) versus the Taxus Liberté
PES (Boston Scientiﬁc, Natick, Massachusetts) in the
treatment of coronary lesions. The BioFreedom
device (BFD) was tested with 2 drug formulations:
BFD “standard dose” and BFD “low dose” (BFD-LD).
Inclusion criteria were: age $18 years; symptoms
of stable or unstable angina, and/or presence of a
positive functional test for ischemia; single de novo
target lesion #14 mm in length, with stenosis 50% to
99%, in native coronary vessel 2.5 to 3.0 mm in diam-
eter; acceptable candidate for coronary artery bypass
graft surgery; and agreement to undergo all protocolFIGURE 1 Polymer-Free BioFreedom Biolimus
A9-Coated Stent
Illustration of the stent platform showing selectively micro-
structured porous surface in the abluminal (outer) side, and
luminal polished surface in the luminal (inner) side.follow-ups (FUs), including 1 angiographic re-
evaluation. Key exclusion criteria were:
myocardial infarction <72 h; left main, ostial
location; moderate or severe calciﬁcation, as
visible by ﬂuoroscopy; target lesion involving
a side branch >2.0 mm in diameter; thrombus;
documented left ventricular ejection frac-
tion <30% assessed within 6 months prior to
procedure by echocardiography, during pre-
vious angiography, or asmeasured during pre-
procedure angiography; known hypersensi-
tivity or contraindication to antithrombotic
therapy; and concurrent medical condition
with life expectancy <18 months.The study complied with the Declaration of Hel-
sinki regarding investigation in humans, followed
ISO-14155:2003, and was approved by the local ethics
committees at the participant institutions. All pa-
tients provided written informed consent prior to
procedure.
STUDY DEVICE. The study device has been detailed
elsewhere (18). In brief, it incorporates a 316L
stainless-steel platform, which has beenmodiﬁedwith
a proprietary surface treatment resulting in a selec-
tively microstructured abluminal surface (Figure 1).
The selectively microstructured surface allows adhe-
sion of the antiproliferative agent (biolimus) to
the abluminal surface of the stent without a polymer
or binder. The drug dose for the BFD device was
15.6 mg/mm of stent length, whereas a half-dose
(7.8 mg/mm of stent length) was used for BFD-LD. As
for release kinetics, approximately 90% of biolimus
was released from the stent <48 h after implant, irre-
spectively of dose formulation, with the remaining
being released in up to 28 days.
RANDOMIZATION AND PROCEDURE. Eligible pa-
tients were randomized in a 1:1:1 ratio for treatment
with BFD, BFD-LD, and PES. The ﬁrst subset of ran-
domized patients (Cohort 1) was assigned to 4-month
angiographic FU, as the intention was to have an early
assessment of efﬁcacy for a novel DCS with boost
drug release. The second subset of randomized pa-
tients (Cohort 2) was assigned to 12-month angio-
graphic FU. Percutaneous coronary intervention was
performed according to standard guidelines. Lesion
pre-dilation was recommended by protocol; only 1
stent was allowed per target lesion, even though
additional stent(s) (same as group allocation) could be
used in bailout situations. The BioFreedom stents
were available in 2.5 and 3.0 mm diameters and 14
and 18 mm lengths; PES were 2.5, 2.75, and 3.0 mm in
diameter, and 12, 16, and 20 mm in length. Multi-
vessel percutaneous coronary intervention at index
FIGURE 2 Study Flow
Group allocation in the BioFreedom FIM (First-in-Man) trial. Patients were randomized in a 1:1:1 ratio to treatment with the BioFreedom
“standard dose” (BFD) and the BioFreedom “low dose” (BFD-LD) stents versus paclitaxel-eluting stents (PES). The ﬁrst 75 patients enrolled
were assigned to 4-month angiographic follow-up (FU) (Cohort 1); the subsequent 107 patients were assigned to 12-month angiographic FU
(Cohort 2). Long-term FU for clinical endpoints was available in 175 of 182 patients.
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54procedure including treatment of a nontarget lesion
in a nontarget vessel was allowed, given that the
nontarget lesion had to be successfully treated ﬁrst,
with any nonstudy device, at the operator’s discre-
tion. At post-procedure, DAPT was prescribed for at
least 6 months.
ENDPOINTS AND DATA MANAGEMENT. The primary
endpoint was in-stent late lumen loss (LLL), as
determined by independent quantitative coronary
angiography (QCA) analysis, at 12-month angio-
graphic FU (Cohort 2). Key secondary endpoints
included: in-stent LLL at 4 months (Cohort 1); major
adverse cardiac events, deﬁnite or probable stent
thrombosis (ST) (19); clinically-driven target-lesion
revascularization (TLR) and clinically-driven target-
vessel revascularization at hospital discharge and at
30-day, 4-month, 12-month, and yearly up to 5-year
FU; angiographic binary restenosis at 4- (Cohort 1)
and 12-month (Cohort 2) FU; and lesion andprocedural success. Data coordination and manage-
ment, statistical analysis, and unblinding of the data
were performed by an independent data coordina-
ting center (Cardiovascular Research Foundation,
New York, New York). Primary data collection
was performed at each clinical site following stand-
ard procedures including source veriﬁcation, elec-
tronic completion of individual Case Report Forms,
physical monitoring, and remittance of proper
source-documentation. By protocol, clinical FU con-
sisting of medical visits were scheduled at 1-, 4-, and
12-month and yearly up to 5-year FU. Full deﬁnitions
and details of the study organization are provided in
the Online Appendix.
ANGIOGRAPHIC ANALYSIS. Serial coronary angio-
graphic studies were obtained after intracoronary
administration of nitroglycerin (100 to 200 mg, unless
contraindicated) in 2 orthogonal matching views at
pre-procedure, post-procedure and FU. Angiographic
TABLE 1 Baseline Clinical Characteristics of the Overall Study Population
Comparing BFD and BFD-LD Versus PES
BFD (a) BFD-LD (b) PES (c)
p Value
(a) vs. (c) (b) vs. (c)
n 60 62 60
Age, yrs 68.6  9.0 65.0  9.4 67.9  8.0 0.55 0.13
Male 40 (66.7) 47 (75.8) 40 (66.7) >0.99 0.27
Diabetes mellitus 17 (28.3) 18 (29.0) 15 (25.0) 0.68 0.62
Hypertension 54 (90.0) 50 (80.6) 51 (85.0) 0.41 0.52
Dyslipidemia 41 (68.3) 45 (73.8) 45 (75.0) 0.42 0.88
Smoking (current) 10 (16.9) 12 (20.3) 7 (12.3) 0.48 0.24
Family history of CAD 16 (32.7) 21 (38.2) 18 (38.3) 0.56 0.99
Prior MI 12 (20.0) 13 (21.3) 11 (18.3) 0.82 0.68
Prior PCI 19 (31.7) 27 (44.3) 27 (45.8) 0.11 0.87
Renal insufﬁciency* 5 (8.3) 3 (4.8) 1 (1.7) 0.09 0.33
Clinical presentation
Stable angina 49 (81.7) 47 (75.8) 46 (76.7) 0.50 0.91
Unstable angina 7 (11.7) 8 (12.9) 4 (6.7) 0.34 0.25
Silent ischemia 2 (3.3) 6 (9.7) 6 (10.0) 0.14 0.95
Values are n, mean  SD, or n (%). *Deﬁned as baseline serum creatinine $2.0 mg/dl.
BFD ¼ BioFreedom “standard dose” stents; BFD-LD ¼ BioFreedom “low dose” stents;
CAD ¼ coronary artery disease; MI ¼ myocardial infarction; PES ¼ Taxus paclitaxel-eluting stents;
PCI ¼ percutaneous coronary intervention.
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55analysis was performed ofﬂine by experienced oper-
ators blinded to group allocation, procedural data,
and clinical outcomes at an independent core
laboratory (Cardiovascular Research Center, São
Paulo, Brazil). Quantitative analysis was performed
with validated 2-dimensional software for QCA anal-
ysis (QAngio XA version 7.2, Medis, Leiden, the
Netherlands) (Online Appendix). LLL was the change
in minimum lumen diameter from the post-stent
implantation angiogram to FU; binary restenosis was
deﬁned as stenosis $50% at angiographic FU. QCA
measurements were reported: “in-stent,” within the
stented segment; “in-segment,” spanning the stented
segment plus the 5-mm proximal and distal peristent
areas; and at 5-mm proximal and distal peristent
edges (outside of the stent).
STATISTICAL ANALYSIS. The sample size calculation
for the BioFreedom FIM trial was based on the ex-
pected in-stent LLL results at 12-month angiographic
FU (Cohort 2), given that this randomized trial would
measure the noninferiority of the BFD (“standard-
dose”) group compared with the PES group. The null
hypothesis (Ho) for the primary endpoint was that the
BFD group would have a mean in-stent LLL at
12 months that exceeds that of the PES group by at
least a pre-speciﬁed margin of d (delta), that is,
0.24 mm. The alternative hypothesis (Ha) was that
the BFD group would have in-stent LLL at 12 months
that is lower than the PES group plus d. Therefore,
rejection of the null hypothesis would indicate that
the BFD group is noninferior to the PES group in re-
gard to 12-month in-stent LLL. The null and alterna-
tive hypotheses of interest are the following:
 Ho: m BFD $ m Taxus þ d;
 Ha: m BFD < m Taxus þ d;
where m BFD is the mean in-stent LLL for the BFD arm,
and m PES is the mean in-stent LLL for the PES active
control arm. The pre-speciﬁed margin (delta of 0.24
mm) was considered because it yields less than one-
half of the estimated SD of in-stent LLL (0.5 mm), as
estimated from prior studies (20). In addition, because
previous data suggest that biolimus-eluting stents
perform better than PES, it was assumed that the in-
stent LLL at 12-month FU for the BFD group would
be at least 0.12 mm lower than the PES group
(15,16,18,20). Hence, a minimum sample size of 32 pa-
tients in each study arm of Cohort 2 would give >80%
power at 1-sided a (alpha) of 0.025 to reject the null
hypothesis in favor of noninferiority of the BFD arm
relative to the PES arm. Anticipating up to 10% lost to
angiographic FU, the minimal sample size per ran-
domized group in Cohort 2 was increased byapproximately 10% (35 patients). As for Cohort 1, there
were no formal statistical assumptions as the intention
was to have an early evaluation of efﬁcacy at 4-month
angiographic FU.
Categorical variables are expressed as numbers and
percentages (or frequencies) of the total. Continuous
variables are expressed as mean  SD or median
(interquartile range) when appropriate, on the basis of
their distribution pattern. Statistical comparisons
were conducted between BFD and PES and between
BFD-LD and PES. Categorical variables were compared
with chi-square or Fisher exact tests. Continuous var-
iables were compared for superiority with the Student
t test if normality was present or Wilcoxon rank sum
test in case of non-normality. Kaplan-Meier event
rates were compared using the log-rank test. Hazard
ratios (HRs) with 95% conﬁdence intervals were
calculated using Cox proportional hazards regression.
All statistical analyses were performed using SAS
software version 8.2 or higher (SAS Institute Inc.,
Cary, North Carolina). A p value <0.05 was consid-
ered statistically signiﬁcant.
RESULTS
A total of 182 patients were enrolled between
September 2008 and June 2009 at 4 sites in Germany;
the ﬁrst 75 randomized patients were allocated in
Cohort 1, and the subsequent 107 randomized pa-
tients were allocated in Cohort 2. The majority of
patients (92%) underwent angiographic FU at their
TABLE 2 Angiographic Data of the Overall Study Population Comparing BFD and BFD-LD Versus PES
BFD (a) BFD-LD (b) PES (c)
p Value
(a) vs. (c) (b) vs. (c)
n (patients/lesions) 60/60 62/63* 60/60
Target coronary vessel
Left anterior descending 21 (35.0) 30 (48.4) 18 (30.0) 0.56 0.04
Left circumﬂex 15 (25.0) 12 (19.4) 17 (28.3) 0.68 0.24
Right coronary artery 24 (40.0) 20 (32.3) 25 (41.7) 0.85 0.28
Calcium (moderate/severe) 13 (22.0) 13 (20.6) 18 (30.0) 0.32 0.23
Lesion class B2/C† 26 (44.1) 28 (44.4) 34 (56.7) 0.17 0.18
Pre-procedural TIMI ﬂow 3 54 (90.0) 53 (85.5) 54 (90.0) >0.99 0.45
QCA
Pre-procedure
Lesion length, mm 10.6 (9.3–13.9) 11.3 (9.8–13.6) 11.2 (9.5–14.0) 0.41 0.72
RD, mm 2.8 (2.5–3.0) 2.8 (2.5–3.0) 2.8 (2.5–3.0) 0.99 0.92
MLD, mm 0.6 (0.3–0.9) 0.6 (0.4–0.9) 0.7 (0.5–0.9) 0.53 0.59
% DS 76.0 (64.3–87.6) 77.2 (67.0–85.8) 75.9 (67.2–83.6) 0.66 0.58
Post-procedure
RD, mm 2.9 (2.6–3.0) 2.8 (2.5–3.0) 2.8 (2.6–2.9) 0.90 0.85
In-stent
Mean diameter, mm 2.9 (2.6–3.0) 2.9 (2.6–3.0) 2.9 (2.6–3.0) 0.92 0.88
MLD, mm 2.7 (2.3–2.8) 2.6 (2.3–2.8) 2.6 (2.4–2.8) 0.40 0.47
% DS 6.2 (3.9–11.5) 7.4 (4.5–9.9) 6.1 (3.6–9.4) 0.68 0.38
Acute gain, mm 2.0 (1.6–2.2) 1.9 (1.7–2.2) 1.9 (1.7–2.2) >0.99 0.71
In-segment
MLD, mm 2.3 (2.0–2.5) 2.2 (2.1–2.5) 2.2 (2.0–2.6) 0.71 0.81
% DS 17.2 (9.4–24.3) 16.9 (12.0–23.0) 19.1 (12.0–24.0) 0.98 0.89
Acute gain, mm 1.6 (1.3–2.0) 1.6 (1.4–1.8) 1.6 (1.3–2.0) 0.78 0.97
Proximal edge
MLD, mm 2.6 (2.3–2.8) 2.5 (2.2–2.9) 2.5 (2.3–2.8) 0.88 0.74
% DS 8.6 (5.7–16.1) 9.4 (4.8–16.6) 12.5 (5.8–18.3) 0.38 0.47
Distal edge
MLD, mm 2.3 (2.0–2.6) 2.3 (2.1–2.6) 2.2 (2.0–2.5) 0.92 0.35
% DS 11.9 (8.3–18.9) 11.0 (6.1–15.9) 11.8 (8.0–17.6) 0.43 0.38
Balloon-artery ratio 1.2 (1.1–1.2) 1.1 (1.1–1.2) 1.1 (1.1–1.2) 0.66 0.99
Values are n (%) or median (interquartile range). *One patient in BFD-LD had 2 target lesions treated within the same target vessel. †Only type B, according to the modiﬁed
American College of Cardiology/American Heart Association lesion classiﬁcation.
DS ¼ diameter stenosis; MLD¼minimum lumen diameter; QCA ¼ quantitative coronary angiography; RD ¼ reference diameter; TIMI ¼ Thrombolysis In Myocardial Infarction;
other abbreviations as in Table 1.
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56pre-assigned timeframe—either 4 or 12 months—and
98.9% (180 of 182) completed 12-month clinical FU
(Figure 2). Considering the overall population, base-
line characteristics were well matched between the
groups (Tables 1 and 2). All lesions were successfully
treated, and procedural success was achieved in all
but 1 patient in the BFD-LD group (Online Table 1).
QCA ANALYSIS. Pre- and post-procedure QCA results
were similar in the overall study population (Table 2),
as well as in Cohorts 1 and 2 (Online Table 2). At
4-month FU (Cohort 1), in-stent LLL (secondary
endpoint) was signiﬁcantly lower with BFD and BFD-
LD versus PES (0.08 and 0.12 mm vs. 0.37 mm,
respectively; p < 0.0001 for BFD vs. PES, p ¼ 0.002 for
BFD-LD vs. PES) (Table 3). There were no cases of in-
stent restenosis in both the BFD and BFD-LD groups;conversely, 9.1% (2 of 22) presented with in-stent
restenosis in PES. Moreover, focal edge restenosis
was found in 1 case in each group. The primary
outcome was assessed in Cohort 2 (Table 3), and in-
stent LLL was 0.17 mm in BFD versus 0.35 mm in
PES (p ¼ 0.001 for noninferiority; p ¼ 0.11 for supe-
riority); however, in-stent LLL with BFD-LD
(0.22 mm) did not reach signiﬁcance in terms of
noninferiority against PES (p ¼ 0.21) (Figure 3). Cu-
mulative frequency distribution curves for in-stent
minimum lumen diameter are shown in Figure 4. In
addition, in-stent restenosis rates were 6.7% (2 of 30)
and 8.6% (3 of 35) versus 3.2% (1 of 31), whereas in-
segment restenosis was 6.7% (2 of 30) and 14.3% (5
of 35) versus 9.7% (3 of 31), for the BFD, BFD-LD, and
PES groups, respectively (all p values nonsigniﬁcant).
TABLE 3 QCA Results at 4- (Cohort 1) and 12-Month (Cohort 2) Follow-Up Comparing BFD and BFD-LD Versus PES
BFD (a) BFD-LD (b) PES (c)
p Value
(a) vs. (c) (b) vs. (c)
4-Month FU (Cohort 1)
n (lesions) 23 25 22
RD, mm 2.8 (2.5–2.9) 2.7 (2.5–2.9) 2.7 (2.4–3.0) 0.96 0.83
In-stent
Mean diameter, mm 2.7 (2.6–2.9) 2.8 (2.4–3.0) 2.6 (2.2–3.0) 0.32 0.31
MLD, mm 2.5 (2.1–2.7) 2.5 (2.0–2.7) 2.2 (1.6–2.6) 0.09 0.17
% DS 7.6 (4.0–13.6) 10.1 (7.3–17.3) 18.0 (11.3–22.9) 0.002 0.02
LLL, mm 0.08 (0.02–0.14) 0.12 (0.07–0.25) 0.37 (0.14–0.50) <0.0001 0.002
LLL index 0.05 (0.01–0.09) 0.06 (0.04–0.14) 0.19 (0.09–0.31) 0.0002 0.003
In-segment
MLD, mm 2.0 (1.7–2.3) 2.1 (1.9–2.3) 2.0 (1.5–2.3) 0.80 0.44
% DS 25.2 (16.8–33.0) 24.3 (18.8–27.9) 24.6 (20.4–29.8) 0.65 0.50
LLL, mm 0.12 (0.02–0.20) 0.12 (0.06–0.25) 0.18 (0.09–0.42) 0.09 0.35
LLL index 0.06 (0.02–0.17) 0.08 (0.04–0.15) 0.12 (0.07–0.29) 0.15 0.32
Proximal edge
MLD, mm 2.3 (2.0–2.5) 2.4 (2.2–2.6) 2.3 (2.2–2.7) 0.13 0.95
% DS 18.6 (13.3–24.1) 12.0 (8.7–17.1) 16.7 (11.1–24.2) 0.31 0.34
LLL, mm 0.13 (0.04–0.32) 0.13 (0.04–0.26) 0.15 (0.05–0.25) 0.77 0.99
Distal edge
MLD, mm 2.0 (1.8–2.4) 2.2 (1.9–2.4) 2.1 (1.9–2.3) 0.75 0.95
% DS 16.2 (8.2–21.9) 15.3 (11.8–20.1) 12.6 (8.1–19.0) 0.30 0.42
LLL, mm 0.06 (0.01–0.16) 0.11 (0.04–0.31) 0.09 (0.01–0.24) 0.71 0.37
12-Month FU (Cohort 2)
n (lesions) 31 35 31
RD, mm 2.8 (2.5–2.9) 2.8 (2.4–2.9) 2.8 (2.7–2.9) 0.97 0.87
In-stent
Mean diameter, mm 2.8 (2.5–2.8) 2.6 (2.3–2.9) 2.6 (2.5–2.9) 0.76 0.33
MLD, mm 2.4 (2.0–2.6) 2.2 (1.8–2.6) 2.3 (2.0–2.4) 0.49 0.83
% DS 13.8 (9.4–21.3) 13.6 (9.0–39.5) 19.3 (10.0–25.0) 0.21 0.30
LLL, mm 0.17 (0.09–0.39) 0.22 (0.17–0.66) 0.35 (0.22–0.57) 0.11 0.55
LLL index 0.10 (0.05–0.22) 0.12 (0.09–0.35) 0.20 (0.11–0.30) 0.11 0.63
In-segment
MLD, mm 2.0 (1.9–2.4) 2.0 (1.6–2.3) 2.0 (1.9–2.3) 0.85 0.36
% DS 21.8 (14.6–30.9) 23.7 (15.0–45.0) 22.9 (17.1–32.9) 0.60 0.75
LLL, mm 0.17 (0.12–0.35) 0.19 (0.07–0.58) 0.27 (0.08–0.57) 0.52 0.93
LLL index 0.11 (0.06–0.22) 0.12 (0.04–0.33) 0.17 (0.05–0.30) 0.56 0.94
Proximal edge
MLD, mm 2.5 (2.2–2.8) 2.2 (1.8–2.7) 2.5 (2.2–2.8) 0.78 0.09
% DS 11.1 (6.3–18.5) 18.1 (7.8–31.1) 12.4 (6.0–24.1) 0.62 0.16
LLL, mm 0.10 (0.03–0.20) 0.17 (0.06–0.48) 0.07 (0.01–0.25) 0.60 0.01
Distal edge
MLD, mm 2.3 (2.0–2.5) 2.3 (2.0–2.5) 2.2 (1.9–2.5) 0.93 0.72
% DS 12.1 (7.7–21.3) 12.0 (10.2–17.0) 10.1 (7.6–16.7) 0.70 0.56
LLL, mm 0.14 (0.05–0.19) 0.10 (0.05–0.34) 0.10 (0.06–0.19) 0.61 0.91
Values are n or median (interquartile range).
LLL ¼ late lumen loss; other abbreviations as in Tables 1 and 2.
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57CLINICAL OUTCOMES. Kaplan-Meier estimates and
occurrence curves for the composite and individual
clinical endpoints are reported in Table 4 and Figure 5.
Between 1 and 5 years (Online Table 3), clinically
driven TLR, associated with angiographic restenosis
within the treated segment, was found in 2 of 5 casesin BFD, 2 of 4 in BFD-LD, and 1 of 3 in PES. The other
cases of TLR evidenced patent stents, but signiﬁcant
stenoses within the coronary segments adjacent to the
target lesion site (stent þ5-mm proximal/distal
edges). Considering any TLR, event rates were 10.8%
(n ¼ 6) in BFD and 15.1% (n ¼ 9) in BFD-LD versus
FIGURE 3 Late Lumen Loss at Angiographic Follow-Up
Median (SD, bars) in-stent LLL at 4- (Cohort 1, A) and 12-month (Cohort 2, B) angiographic follow-up. Abbreviations as in Figure 2.
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5811.9% (n ¼ 7) in PES (all p values nonsigniﬁcant).
Overall, there were no cases of Academic Research
Consortium deﬁnite or probable ST in any group.
DISCUSSION
In the current analysis, we tested the proof of concept
that a polymer/carrier-free biolimus release via a
microstructured stent surface could be effective in
reducing NIH as compared with PES; results were
positive with BFD, but not with BFD-LD. In addition,
there were similar event rates up to 5 years and no
safety concerns, including absence of Academic
Research Consortium deﬁnite or probable ST in
all groups. Most of the rationale for developing
nonpolymeric DCS has been based on previous ob-
servations that linked synthetic polymers used in
ﬁrst-generation DES with persistent local inﬂamma-
tory and toxic responses, which could lead to
delayed (or lack of) vascular healing, hypersensitivity
reactions, endothelial dysfunction, and even neo-
atherosclerosis; all phenomena that have been asso-
ciated with late and very late recurrences including
ST (1–6,21–23). Overall, durable polymers used in ﬁrst-
generation DES were associated with suboptimal
biocompatibility and mechanical complications; con-
sequently, second-generation DES have incorporated
lower-proﬁle components with thrombus-resistant
properties; also, DES with biodegradable polymers
have shown improved long-term safety comparedwith DES with durable polymers (1–6,17,21–26).
Nonetheless, despite clinical superiority of new-
generation DES over ﬁrst-generation DES, late and
very late events may still occur (17,27). Hence,
nonpolymer-based DCS could offer, at least theoreti-
cally, additional advantages such as: avoiding prob-
lems related to temporary or permanent polymeric
residue; optimizing vascular healing; maintaining
stent surface integrity (as opposed to webbing/
delamination phenomenon seen with polymeric de-
vices); and shortening DAPT post-stent implantation,
reducing bleeding (without compromising safety)
while maintaining efﬁcacy at inhibiting NIH. The
BioFreedom DCS technology was primarily conceived
with a dose of biolimus identical to the reference dose
applied in the BioMatrix biolimus-eluting stent
(Biosensors Europe SA, Morges, Switzerland) with a
biodegradable polymer, as this device has demon-
strated high efﬁcacy and sustained safety in multiple
clinical scenarios (15–17). Yet, due to the high lip-
ophilicity property of Biolimus (w10 greater than
sirolimus) (14), it was rationalized that a “lower dose”
of biolimus could be as efﬁcacious and safe as the
“standard drug dose,” with potential additional ad-
vantages in terms of minimizing local inﬂammatory
response (due to less drug load) and providing
faster and enhanced vessel healing. Such assump-
tions were supported by prior pharmacokinetics
analysis with biolimus (14) and pre-clinical studies
with BioFreedom stents (18), which demonstrated
FIGURE 4 Distribution of MLD at Pre-Procedure, Post-Procedure and Follow-Up
Cumulative frequency distribution curves for in-stent minimum lumen diameter (MLD) for Cohorts 1 (4-month angiographic follow-up, A) and 2 (12-month angiographic
follow-up, B). Abbreviations as in Figure 2.
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TABLE 4 Clinical Outcomes of the Overall Study Population Comparing BFD and BFD-LD Versus PES
Cumulative Events BFD (a) BFD-LD (b) PES (c)
HR (95% CI) p Value
(a) vs. (c) (b) vs. (c) (a) vs. (c) (b) vs. (c)
0–30 days
MACE 0 (0) 1 (1.6) 0 (0) — — — 0.33
All-cause death 0 (0) 0 (0) 0 (0) — — — —
Cardiac 0 (0) 0 (0) 0 (0) — — — —
Noncardiac 0 (0) 0 (0) 0 (0) — — — —
MI 0 (0) 1 (1.6) 0 (0) — — — 0.33
Clinically driven TLR 0 (0) 0 (0) 0 (0) — — — —
Clinically driven TVR 0 (0) 0 (0) 0 (0) — — — —
ST (ARC deﬁnite/probable) 0 (0) 0 (0) 0 (0) — — — —
0–4 months
MACE 0 (0) 2 (3.3) 1 (1.7) 0.00 1.96 (0.18–21.57) 0.32 0.58
All-cause death 0 (0) 0 (0) 0 (0) — — — —
Cardiac 0 (0) 0 (0) 0 (0) — — — —
Noncardiac 0 (0) 0 (0) 0 (0) — — — —
MI 0 (0) 1 (1.6) 0 (0) — — — 0.33
Clinically driven TLR 0 (0) 0 (0) 1 (1.7) 0.00 0.00 0.32 0.31
Clinically driven TVR 0 (0) 2 (3.3) 1 (1.7) 0.00 1.93 (0.18–21.34) 0.32 0.58
ST (ARC deﬁnite/probable) 0 (0) 0 (0) 0 (0) — — — —
0–12 months
MACE 3 (6.1) 7 (11.6) 3 (5.5) 0.98 (0.20–4.83) 2.36 (0.61–9.12) 0.98 0.20
All-cause death 1 (1.8) 0 (0) 0 (0) — — 0.34 —
Cardiac 1 (1.8) 0 (0) 0 (0) — — 0.34 —
Noncardiac 0 (0) 0 (0) 0 (0) — — — —
MI 1 (2.6) 1 (1.6) 0 (0) — — 0.32 0.33
Clinically driven TLR 1 (1.7) 4 (6.7) 3 (5.5) 0.34 (0.03–3.22) 1.30 (0.29–5.80) 0.32 0.73
Clinically driven TVR 3 (5.1) 8 (14.0) 3 (5.5) 1.02 (0.21–5.06) 2.70 (0.72–10.19) 0.98 0.13
ST (ARC deﬁnite/probable) 0 (0) 0 (0) 0 (0) — — — —
0–60 months
MACE 14 (23.8) 16 (26.4) 12 (20.3) 1.18 (0.55–2.56) 1.41 (0.67–2.98) 0.67 0.37
All-cause death 5 (8.5) 7 (11.6) 4 (6.9) 1.27 (0.34–4.74) 1.75 (0.51–5.99) 0.72 0.36
Cardiac 3 (5.2) 2 (3.6) 0 (0) — — 0.08 0.16
Noncardiac 2 (3.5) 5 (8.3) 4 (6.9) 0.51 (0.09–2.79) 1.25 (0.34–4.66) 0.43 0.74
MI 3 (5.3) 2 (3.3) 2 (3.5) 1.58 (0.26–9.44) 1.02 (0.14–7.21) 0.61 0.99
Clinically driven TLR 6 (10.8) 8 (13.4) 6 (10.2) 1.00 (0.32–3.11) 1.35 (0.47–3.91) >0.99 0.57
Clinically driven TVR 11 (19.3) 13 (21.7) 9 (15.4) 1.27 (0.53–3.08) 1.54 (0.66–3.59) 0.59 0.32
ST (ARC deﬁnite/probable) 0 (0) 0 (0) 0 (0) — — — —
Values are n (%) or HR (95% CI).
ARC ¼ Academic Research Consortium; CI ¼ conﬁdence interval; HR ¼ hazard ratio; MACE ¼ major adverse cardiac events (the composite of all-cause death, myocardial
infarction, emergent bypass surgery, or target lesion revascularization); MI ¼ myocardial infarction; ST ¼ stent thrombosis; TLR ¼ target lesion revascularization; TVR ¼ target
vessel revascularization; other abbreviations as in Tables 1 to 3.
Costa et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 1 , 2 0 1 6
Polymer-Free Biolimus-Coated Stents for De Novo Lesions J A N U A R Y 1 1 , 2 0 1 6 : 5 1 – 6 4
60high efﬁcacy in reducing NIH, optimal vessel healing,
and minimal local inﬂammatory response with both
BFD and BFD-LD. In the current analysis, the BFD
group met the primary outcome of noninferiority in
terms of in-stent LLL at 12-month angiographic FU
(p < 0.001), with a statistically nonsigniﬁcant trend
toward superiority (p ¼ 0.11) versus the PES group. As
for clinical events, there were no signiﬁcant differ-
ences, and most recurrences after 1 year appeared to
be related to coronary artery disease progression
occurring in coronary segments other than the treated
site. Of note is the fact that the BioFreedom FIM trialwas not designed, sized, or statistically powered to
demonstrate superiority of the study groups versus
the active control group in terms of LLL or any other
angiographic or clinical endpoint. Nevertheless, 12-
month in-stent LLL with BFD was relatively low
(0.17 mm) and was comparable to the most effective
DES systems tested to date (15,24,25,28). Interest-
ingly, the BFD-LD group did not meet the primary
endpoint of noninferiority versus PES (p ¼ 0.21); in
addition, it showed numerically higher rates of
angiographic and clinical restenosis (Table 4), thus
suggesting inferior efﬁcacy at inhibiting NIH. On the
FIGURE 5 Kaplan-Meier Curves Showing Event Rates Stratiﬁed by Group Allocation
Major adverse cardiac events (A), cardiac death (B), myocardial infarction (C), any target lesion revascularization (TLR) (D), clinically driven target TLR (E), and clinically
driven target vessel revascularization (TVR) (F). Abbreviations as in Figure 2.
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62basis of these results, the BioFreedom clinical pro-
gram was continued with the BFD stent only, as proof
of concept was not demonstrated with BFD-LD.
Uncontrolled or boost drug release has been asso-
ciated with poor efﬁcacy and DCS failure (10–13);
however, drug dose and pharmacodynamics may play
an important role. In the DELIVER (The RX ACHIEVE
Drug-Eluting Coronary Stent System [CSS] In the
Treatment of Patients with De NoVo NativE CoronaRy
Lesions) trial, only a marginal beneﬁt in terms of in-
stent LLL was observed at 8-month FU with the
polymer-free paclitaxel-coated stent versus the un-
coated control stent (0.81 mm vs. 0.98 mm; p ¼ 0.003,
respectively); however, this difference did not trans-
late into signiﬁcant reductions in binary restenosis or
TLR rates. By that time, it was estimated that up to
40% of the drug was lost during stent delivery; also,
release kinetics was considered “too fast” (within
days to weeks) (10). On the contrary, the Taxus PES
with durable polymer (used as active control group in
our study) had a much slower drug release (<10% in
30 days), with approximately 67% less drug compared
with the DCS used in the DELIVER trial; yet, in-stent
LLL in the TAXUS-IV trial was considerably lower
(0.37 mm), despite identical drug (paclitaxel) (20).
Similarly, polymer-free sirolimus-eluting stents seem
to perform worse in terms of efﬁcacy compared with
polymer-based sirolimus-eluting stents (12). Both
BFD and BFD-LD shared identical stent design and
release kinetics, but differed on drug dosage (BFD-LD
with one-half dose of BFD). Therefore, we may spec-
ulate that the main mechanism associated with the
negative results in terms of efﬁcacy found with BFD-
LD is insufﬁcient drug amount, rather than release
kinetics. Furthermore, the BFD DCS and the Bio-
Matrix DES have completely different drug release
kinetics (BioMatrix: w70% in 30 days; BioFreedom:
w90% in 48 h); still, in-stent LLL appears to be
similar, despite boost release with BFD (15,16,18).
There are a few possibilities to explain these ﬁndings.
The innovative modiﬁed surface technology creating
a selectively microstructured textile reservoir in
BioFreedom appears to be effective at holding and
carrying the drug to the target site, where it dissolves
(18). Moreover, biolimus may offer signiﬁcant ad-
vantages compared with other “limus” agents, as it
may improve pharmacokinetics due to its high lip-
ophilicity and, consequently, optimize bioavailability
with rapid distribution into the arterial wall during
the initial hours after stent implant; this allows
achievement of faster therapeutic concentrations and
extended duration of treatment effect (14,18), which
may counterbalance the potentially negative effects
of boost release.STUDY LIMITATIONS. First, we studied relatively
simple and discrete lesions; thus, caution should be
used before generalizing our results to patients with
more complex disease. Second, PES represents a
somewhat outdated DES technology, which has
demonstrated to be inferior to current-generation
DES (27); however, the reasons we chose this active
comparator were: 1) it was still largely used at the
time of protocol design and enrollment start (29,30);
2) there was robust evidence, without major concerns
in terms of safety and clinical efﬁcacy by that time
(29–31); 3) it had been used as control therapy in
multiple other studies; and 4) on the basis of its
historical LLL (0.37 mm) (20), it was thought to be
the right comparator considering a noninferiority
study design and the assumptions made for the pri-
mary endpoint. Third, even though there were no
signiﬁcant differences in clinical outcomes and
absence of deﬁnite/probable ST up to 5 years, no
conclusions regarding safety and efﬁcacy can be
made, as the BioFreedom FIM trial was not statisti-
cally powered to demonstrate noninferiority or
superiority in clinical endpoints; therefore, future
large-scale studies are needed to demonstrate the
clinical implications of the BFD stent, particularly in
comparison with newer-generation DES. Speciﬁcally,
due to its design and concept, the BFD stent may offer
less dependence on prolonged DAPT than polymer-
coated DES (18), and to test this hypothesis, the 2,456
patient randomizedLEADERSFREEtrial (NCT01623180)
is currently ongoing (32). On the basis of our ﬁndings,
we may speculate that BFD is likely to improve clin-
ical efﬁcacy against uncoated stents, but the impli-
cations regarding safety in such complex populations
as expected in this trial are yet to be determined.
CONCLUSIONS
The polymer-free BioFreedom biolimus-coated stents
with a standard dose (BFD) demonstrated high efﬁ-
cacy in inhibiting NIH at 4- and 12-month angio-
graphic re-evaluations and were noninferior to the
PES in terms of in-stent LLL, a surrogate of NIH, at
12-month FU. In addition, there were no safety con-
cerns up to 5 years, including similar rates of major
adverse cardiac events and absence of deﬁnite or
probable ST in all groups.
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PERSPECTIVES
WHAT IS KNOWN? Nonpolymeric DCS have been
introduced as an alternative to polymeric DES to avoid
problems related to temporary or permanent polymeric
residue that could lead to chronic inﬂammation and local
toxicity; however, the absence of a drug carrier had been
associated with lesser efﬁcacy at inhibiting NIH.
WHAT IS NEW? In the BioFreedom ﬁrst-in-man trial, the
proof of concept that a polymer-free BA9 (biolimus)
release via a microstructured stent surface could be as
effective in reducing NIH as a ﬁrst-generation PES was
demonstrated, as the BioFreedom drug-coated stent with
a “standard dose” of biolimus (15.6 mg/mmof stent length)
was signiﬁcantly noninferior in terms of in-stent late
lumen loss, a surrogate of NIH, as compared with the PES
active control group at 12-month angiographic follow-up
(0.17 mm vs. 0.35 mm, respectively; p < 0.001).
WHAT IS NEXT? Due to its design and concept, the
BioFreedom drug-coated stent may offer less depen-
dence on prolonged dual antiplatelet therapy than
polymer-coated DES while maintaining efﬁcacy; thus, it
may be suitable for those who are at high risk for
bleeding. The ongoing LEADERS FREE trial is investi-
gating the clinical effect of the BioFreedom technology
versus uncoated stents in complex patients at high risk
for bleeding receiving short-term (1-month) dual anti-
platelet therapy; furthermore, future large-scale studies
are needed to investigate BioFreedom’s clinical implica-
tions in comparison with newer-generation DES.
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